Pulse Biosciences Inc
Suletud
SektorTervishoid
53.84 -0.55
Ülevaade
Aktsiahinna muutus
24h
Min
52.9
Max
56.99
Sissetulek | -6.1M -25M |
|---|---|
Müük | 33K 434K |
Aktsiakasum | -0.36 |
Kasumimarginaal | -5,681.336 |
Töötajad | 116 |
EBITDA | -5.8M -25M |
Järgmine tulemuste avaldamine | 4. nov 2026 |
|---|
Turukapital | 1.2B 3.8B |
|---|---|
Eelmine avamishind | 54.39 |
Eelmine sulgemishind | 53.84 |
Uudiste sentiment
By Acuity
50%
50%
144 / 339 Pingereas Healthcare
Pulse Biosciences Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Pulse Biosciences Inc Prognoos
Sentiment
By Acuity
144 / 339 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.